Relationship between ALZpath pTau217 and cognitive test performance in a primary care sample
Abstract Background Blood biomarkers are a promising tool for identifying Alzheimer's disease (AD), particularly in primary care settings where AD and related dementias are frequently undiagnosed. More information in real‐world clinical cohorts is needed to increase confidence in the utility of plasma biomarkers, particularly phosphorylated tau at threonine 217 (pTau217), which has demonstrated reliability in indicating AD pathology (Devanarayan V, et al., 2024) and strong correlations with positive amyloid PET scans (Ashton N, et al., 2023). This study aimed to examine the relationship of plasma pTau217 to cognitive test performance in a real‐world primary care cohort. Method Sixty‐eight older adults completed the Quick Mild Cognitive Impairment (Qmci) screen during a routine primary care visit and a blood draw on the same day or within six weeks. Participants with elevated ALZpath pTau217 levels (> 0.63 ng/L) were classified as positive, and those with pTau217 levels between 0.34‐0.63 ng/L were classified as intermediate (Mammel AE, et al., 2025). A subset of participants ( n = 58) completed a neuropsychological test battery (NTB) consisting of language, memory, and executive functioning (EF) measures. Participants were considered cognitively impaired if they had two or more demographically adjusted T scores < 40 within the language, memory, or EF domains or one demographically adjusted T score < 40 in each of the three domains. Result Average age was 68.8 years (69% female, 90% White), and 26% were APOEε4. Five participants (7%) had positive pTau217 levels, and 15 (22%) had intermediate levels. Of the five pTau217 positive participants, none were cognitively impaired on the Qmci, but three were cognitively impaired on the NTB, two in the memory domain and one in memory and EF. Of the 15 with intermediate pTau217 levels, two were impaired on the Qmci and four were impaired on the NTB, all in the memory domain only. Higher average concentrations of pTau217 correlated significantly with lower composite memory T scores ( r = ‐.26; p = 05) but not global, language, or EF T scores. Conclusion Elevated levels of pTau217 were relatively low in this generally cognitively intact primary care cohort, but showed adequate concordance with cognitive performance, especially memory.
Authors
- Lee Honigberg (ORCID: https://orcid.org/0000-0003-0996-1062)
- Scott Selinger (ORCID: https://orcid.org/0000-0001-5336-3778)
- L Guadagno
- Robin C. Hilsabeck (ORCID: https://orcid.org/0000-0001-8386-1508)
- Andreas Jeromin
- Carolynne C. Holbrook
- Heather E. Cuevas (ORCID: https://orcid.org/0000-0003-4314-6686)
- Joshua T Chang
- Donald Biehl
- Nusha Kheradbin
- Claire Harrison
- Teodora Stoica
- Tomequa Sears
- Michael Metke
- Ryan Huebinger
- Ling‐Yu Chang
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Structural Analytics (United States) (US)
- Banyan Biomarkers (United States) (US)
- Western Washington University (US)
- The University of Texas at Austin (US)
- The University of Texas Southwestern Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_107422
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00